Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $6.00 at Chardan Capital
Century Therapeutics (NASDAQ:IPSC – Get Free Report) had its target price lowered by research analysts at Chardan Capital from $7.00 to $6.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Several other research analysts have also weighed in on IPSC. Piper […]
Century Therapeutics (NASDAQ:IPSC – Get Free Report) had its target price lowered by research analysts at Chardan Capital from $7.00 to $6.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Several other research analysts have also weighed in on IPSC. Piper […]
